A continuing medical education and nursing continuing professional development activity provided by NAMCP and AAMCN.
This activity is an archive from the live session from the 2025 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.
This activity is valid from August 1, 2025 to August 1, 2026
Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the evaluation and post test. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete it. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the "download" button after completing the post test.
Audience: This activity is intended for healthcare professionals practicing in managed care environments.
This activity is supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC
Description:
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes inflammation and the formation of ulcers in the lining of the colon and rectum. UC affects around three million people in the United States and is most seen in people aged 20 to 40 years. The diagnosis of UC is typically seen through a combination of clinical symptoms, endoscopic findings, histological examination, and exclusion of other causes of colitis, such as infections. There are certain tests, such as serological markers and fecal calprotectin, that can help, but they are not as definitive when making an accurate diagnosis. Genetic biomarkers and testing continue to gain momentum when looking at diagnostic tools to help with more precise disease categorization and personalized treatment plans.
Therapeutic advances are transforming outcomes and treatment goals for many people living with UC, but patients continue to experience setbacks in their personalized care. Immediate patient goals are to relieve symptoms to help improve a patient's quality of life, while long-term goals include maintenance of a corticosteroid-free clinical remission, mucosal healing, and endoscopic remission. Traditional therapy for the drug management of UC has involved the use of 5-aminosalicylic acid (5-ASA) compounds, Sulfasalazine, and corticosteroids. These therapeutic pathways have proven effective, but newer options, including alpha-4-integrin blockade agents, anti-CD3 antibodies, and biologic therapies, offer the prospect of improved dosing and compliance with traditional molecules. A better understanding of treatments will offer managed care professionals' essential information on giving patients the best treatments available to improve quality of life and outcomes. Studies show that inflammation due to an overreaction of the IL-23 pathway can play a crucial role in how UC develops into a chronic disease. One successful treatment option shows a significant reduction in inflammation using a dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. As these new treatments continue to impress and others begin to come out, it is essential to determine which treatments are preferred based on safety and efficacy data that prove clinical significance to help improve patient outcomes.
Upon completion of this activity, participants will be able to:
Faculty:
Jordan Axelrad, MD, MPH, FACG
Co-Director, IBD Center at NYU Langone Health
Associate Professor of Medicine
NYU Grossman School of Medicine
Jordan.Axelrad@nyulangone.org
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Axelrad has served as a consultant for Abbvie, Abviax, Adiso, Biomerieux, Bristol-Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, and Sanofi. He has received grant/research support from BioFire Diagnostics and Genentech All relevant financial relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each physician should claim credit commensurate with the extent of their participation in the activity.
The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.
This activity is supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC
NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.